BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kalogeridi MA, Zygogianni A, Kyrgias G, Kouvaris J, Chatziioannou S, Kelekis N, Kouloulias V. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol 2015; 7(1): 101-112 [PMID: 25625001 DOI: 10.4254/wjh.v7.i1.101] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 74] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Lariviere MJ, Santos PMG, Hill-kayser CE, Metz JM. Proton Therapy. Hematology/Oncology Clinics of North America 2019;33:989-1009. [DOI: 10.1016/j.hoc.2019.08.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 O'Leary C, Soulen MC, Shamimi-Noori S. Interventional Oncology Approach to Hepatic Metastases.Semin Intervent Radiol. 2020;37:484-491. [PMID: 33328704 DOI: 10.1055/s-0040-1719189] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Takamatsu S, Kozaka K, Kobayashi S, Yoneda N, Yoshida K, Inoue D, Kitao A, Ogi T, Minami T, Kouda W, Kumano T, Fuwa N, Matsui O, Gabata T. Pathology and images of radiation-induced hepatitis: a review article. Jpn J Radiol 2018;36:241-56. [DOI: 10.1007/s11604-018-0728-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
5 Yang W, Shao L, Zhu S, Li H, Zhang X, Ding C, Wu X, Xu R, Yue M, Tang J, Kuang B, Fan G, Zhu Q, Zeng H. Transient Inhibition of mTORC1 Signaling Ameliorates Irradiation-Induced Liver Damage. Front Physiol 2019;10:228. [PMID: 30984007 DOI: 10.3389/fphys.2019.00228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Han B, Li C, Meng H, Gomes Romeiro F, Mancuso A, Zhou Z, Levi Sandri GB, Xu Y, Han T, Han L, Shao L, Qi X. Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. Biosci Trends 2019;13:10-22. [PMID: 30799321 DOI: 10.5582/bst.2018.01261] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
7 Lin W, Zhang T, Ding G, Hao L, Zhang B, Yu J, Pang Y, Geng F, Zhan L, Zhou M, Yan Q, Wang Y, Zheng C, Li H. Circular RNA circ‑CCT3 promotes hepatocellular carcinoma progression by regulating the miR‑1287‑5p/TEAD1/PTCH1/LOX axis. Mol Med Rep 2021;23:375. [PMID: 33760147 DOI: 10.3892/mmr.2021.12014] [Reference Citation Analysis]
8 Chen J, Wang D, Zhang X, Fu Q, Yan X, Men K, Dai J, Bi N. Sparing lung tissue with virtual block method in VMAT planning for locally advanced non-small cell lung cancer. NUCL SCI TECH 2022;33. [DOI: 10.1007/s41365-022-01033-x] [Reference Citation Analysis]
9 Brito AF, Abrantes AM, Tralhão JG, Botelho MF. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev 2016;10:302. [PMID: 27994769 DOI: 10.4081/oncol.2016.302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
10 Cao G, Li X, Qin C, Li J. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis. Med Sci Monit. 2015;21:3144-3151. [PMID: 26476711 DOI: 10.12659/msm.894617] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
11 Choi C, Son A, Lee GH, Shin SW, Park S, Ahn SH, Chung Y, Yu JI, Park HC. Targeting DNA-dependent protein kinase sensitizes hepatocellular carcinoma cells to proton beam irradiation through apoptosis induction. PLoS One 2019;14:e0218049. [PMID: 31194786 DOI: 10.1371/journal.pone.0218049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
12 Ikemoto T, Shimada M, Yamada S. Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation. Hepatol Res. 2017;47:23-30. [PMID: 26990590 DOI: 10.1111/hepr.12705] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
13 Erridge S, Pucher PH, Markar SR, Malietzis G, Athanasiou T, Darzi A, Sodergren MH, Jiao LR. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. British Journal of Surgery 2017;104:1433-42. [DOI: 10.1002/bjs.10597] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
14 Yi FT, Lu QP. Mucin 1 promotes radioresistance in hepatocellular carcinoma cells through activation of JAK2/STAT3 signaling. Oncol Lett 2017;14:7571-6. [PMID: 29344203 DOI: 10.3892/ol.2017.7119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
15 Chung YH, Yu CF, Chiu SC, Chiu H, Hsu ST, Wu CR, Yang CL, Hong JH, Yen TC, Chen FH. Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation. Eur J Nucl Med Mol Imaging 2019;46:1733-44. [PMID: 31127350 DOI: 10.1007/s00259-019-04318-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Gerum S, Heinz C, Belka C, Walter F, Paprottka PM, De Toni EN, Roeder F. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting. Strahlenther Onkol 2020;196:334-48. [DOI: 10.1007/s00066-019-01540-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zhu H, Ge K, Lu J, Jia C. Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME. Naunyn-Schmiedeberg's Arch Pharmacol 2019;392:1551-60. [DOI: 10.1007/s00210-019-01701-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Alici-karaca D, Akay B, Yay A, Suna P, Nalbantoglu OU, Karaboga D, Basturk A, Balcioglu E, Baran M. A new lightweight convolutional neural network for radiation-induced liver disease classification. Biomedical Signal Processing and Control 2022;73:103463. [DOI: 10.1016/j.bspc.2021.103463] [Reference Citation Analysis]
19 Wang X, Chen M, Wei R, Wang Z. External Radiation versus Internal Radiation for Patients with Advanced Unresectable HCC -A SEER Based Study. J Cancer 2019;10:1171-80. [PMID: 30854126 DOI: 10.7150/jca.28983] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Gerum S, Heinz C, Belka C, Walter F, Paprottka P, De Toni EN, Roeder F. Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease. Radiat Oncol. 2018;13:100. [PMID: 29843752 DOI: 10.1186/s13014-018-1048-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
21 Chuang HY, Tyan YS, Hwang JJ, Shih KC, Lin WC. A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model. Oncol Lett 2021;21:337. [PMID: 33692869 DOI: 10.3892/ol.2021.12598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Li M, He J, Pan M, Yu Y, Pan Z, Xu B, Zhu J. Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5cm: A propensity score matching study. Dig Liver Dis. 2016;48:1082-1087. [PMID: 27365224 DOI: 10.1016/j.dld.2016.06.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
23 Mandl M, Lieberum M, Dunst J, Depping R. The expression level of the transcription factor Aryl hydrocarbon receptor nuclear translocator (ARNT) determines cellular survival after radiation treatment. Radiat Oncol 2015;10:229. [PMID: 26572229 DOI: 10.1186/s13014-015-0539-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
24 Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2416-2429 [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
25 Alnammi M, Wortman J, Therrien J, Afnan J. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review. Abdom Radiol (NY) 2022. [PMID: 35524803 DOI: 10.1007/s00261-022-03526-0] [Reference Citation Analysis]
26 Yoo GS, Yu JI, Park HC, Hyun D, Jeong WK, Lim HY, Choi MS, Ha SY. Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter? Cancers (Basel) 2020;12:E2395. [PMID: 32847035 DOI: 10.3390/cancers12092395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 De Bari B, Breuneval T, Zeverino M, Godin S, Deantonio L, Geldhof C, Bourhis J, Schaefer N, Moeckli R, Prior J, Ozsahin M. Hepatobiliary scintigraphy allows the evaluation of short-term functional toxicity of liver stereotactic body radiotherapy: Results of a pilot study. PLoS One 2018;13:e0204013. [PMID: 30304045 DOI: 10.1371/journal.pone.0204013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Liu X, Wang S, Guo X, Wei F, Yin J, Zang Y, Li N, Chen D. Exogenous p53 and ASPP2 expression enhances rAdV-TK/ GCV-induced death in hepatocellular carcinoma cells lacking functional p53. Oncotarget 2016;7:18896-905. [PMID: 26934443 DOI: 10.18632/oncotarget.7749] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
29 Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2016; 22(30): 6851-6863 [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
30 Cabibbo G, Reig M, Gadaleta-caldarola G, Galati G, Lombardi G, Mazza G, Marzi L, Saitta C, Nault J, Sacco R. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1. Future Oncology 2016;12:281-4. [DOI: 10.2217/fon.15.323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
31 Yang J, Liang H, Hu K, Xiong Z, Cao M, Zhong Z, Yao Z, Deng M. The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis. Cancer Cell Int 2021;21:92. [PMID: 33549093 DOI: 10.1186/s12935-021-01790-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Jung JM, Kim SH, Giang Phan VH, Thambi T, Lee DS. Therapeutic effects of boronate ester cross-linked injectable hydrogels for the treatment of hepatocellular carcinoma. Biomater Sci 2021;9:7275-86. [PMID: 34609388 DOI: 10.1039/d1bm00881a] [Reference Citation Analysis]
33 Farrag NS, Amin AM. Preliminary evaluation of the radiotherapeutic efficacy of 131I-atorvastatin in rats with hepatocellular carcinoma. NUCL SCI TECH 2020;31. [DOI: 10.1007/s41365-020-00819-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Yan X, Qiu Y. Impact of current staging systems on treatment strategy for HBV-related hepatocellular carcinoma. Cancer Lett 2016;379:220-4. [PMID: 26282785 DOI: 10.1016/j.canlet.2015.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
35 Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review. World J Gastrointest Oncol 2019; 11(5): 367-376 [PMID: 31139307 DOI: 10.4251/wjgo.v11.i5.367] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
36 Cui Y, Liang S, Zhang S, Zhang C, Zhao Y, Wu D, Wang J, Song R, Wang J, Yin D, Liu Y, Pan S, Liu X, Wang Y, Han J, Meng F, Zhang B, Guo H, Lu Z, Liu L. ABCA8 is regulated by miR-374b-5p and inhibits proliferation and metastasis of hepatocellular carcinoma through the ERK/ZEB1 pathway. J Exp Clin Cancer Res 2020;39:90. [PMID: 32430024 DOI: 10.1186/s13046-020-01591-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Yadav P, Mimansa, Munawara R, Kapoor K, Chaturvedi S, Kailasam K, Biswas SK, Bahadur D, Srivastava R, Mishra AK, Shanavas A. Nontoxic In Vivo Clearable Nanoparticle Clusters for Theranostic Applications. ACS Biomater Sci Eng 2022;8:2053-65. [PMID: 35416030 DOI: 10.1021/acsbiomaterials.1c01579] [Reference Citation Analysis]
38 Lin YH, Hung SK, Chiou WY, Lee MS, Shen BJ, Chen LC, Liu DW, Tsai WT, Lin PH, Shih YT, Hsu FC, Tsai SJ, Chan MWY, Lin HY. Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report. Medicine (Baltimore). 2016;95:e4717. [PMID: 27559982 DOI: 10.1097/md.0000000000004717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
39 Bamodu OA, Chang HL, Ong JR, Lee WH, Yeh CT, Tsai JT. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma. Cells 2020;9:E746. [PMID: 32197467 DOI: 10.3390/cells9030746] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
40 Comparetti EJ, Lins PMP, Quitiba J, Zucolotto V. Cancer cell membrane‐derived nanoparticles block the expression of immune checkpoint proteins on cancer cells and coordinate modulatory activity on immunosuppressive macrophages. J Biomedical Materials Res. [DOI: 10.1002/jbm.a.37387] [Reference Citation Analysis]
41 Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
42 Nakano R, Ohira M, Kobayashi T, Imaoka Y, Mashima H, Yamaguchi M, Honmyo N, Okimoto S, Hamaoka M, Shimizu S, Kuroda S, Tahara H, Ide K, Ohdan H. Independent risk factors that predict bile leakage after hepatectomy for hepatocellular carcinoma: Cohort study. Int J Surg 2018;57:1-7. [PMID: 30036692 DOI: 10.1016/j.ijsu.2018.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Susheela SP, Revannasiddaiah S, Basavalingaiah AS, Madabhavi I. Painless lump over the forehead which turned painful: an unusual presentation of hepatocellular carcinoma. BJR Case Rep 2015;1:20150033. [PMID: 30363169 DOI: 10.1259/bjrcr.20150033] [Reference Citation Analysis]
44 Cai J, Xiong Q, Jiang X, Zhou S, Liu T. RNF6 facilitates metastasis and radioresistance in hepatocellular carcinoma through ubiquitination of FoxA1. Experimental Cell Research 2019;374:152-61. [DOI: 10.1016/j.yexcr.2018.11.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
45 Choi C, Lee GH, Son A, Yoo GS, Yu JI, Park HC. Downregulation of Mcl-1 by Panobinostat Potentiates Proton Beam Therapy in Hepatocellular Carcinoma Cells. Cells 2021;10:554. [PMID: 33806487 DOI: 10.3390/cells10030554] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhang Y, Huang B, Chen Z, Yang S. Knockdown of LINC00473 Enhances Radiosensitivity in Hepatocellular Carcinoma via Regulating the miR-345-5p/FOXP1 Axis. Onco Targets Ther. 2020;13:173-183. [PMID: 32021265 DOI: 10.2147/ott.s240113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Hardy-Abeloos C, Lazarev S, Ru M, Kim E, Fischman A, Moshier E, Rosenzweig K, Buckstein M. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization. Int J Radiat Oncol Biol Phys. 2019;105:968-976. [PMID: 31536781 DOI: 10.1016/j.ijrobp.2019.09.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Yu JI, Park HC, Oh D, Noh JM, Jung SH, Kim HY, Shin SW, Cho SK, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial.Int J Hyperthermia. 2016;32:331-338. [PMID: 26915594 DOI: 10.3109/02656736.2016.1144895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
49 Marsico M, Gabbani T, Livi L, Biagini MR, Galli A. Therapeutic usability of two different fiducial gold markers for robotic stereotactic radiosurgery of liver malignancies: A pilot study. World J Hepatol 2016; 8(17): 731-738 [PMID: 27330682 DOI: 10.4254/wjh.v8.i17.731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
50 Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2017;17:911-924. [PMID: 28825506 DOI: 10.1080/14737140.2017.1368392] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
51 Christian-Miller N, Frenette C. Hepatocellular cancer pain: impact and management challenges. J Hepatocell Carcinoma 2018;5:75-80. [PMID: 30050880 DOI: 10.2147/JHC.S145450] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Okuda T, Hayashi N, Takahashi M, Uzuka T, Okita Y, Otani R, Fujinaka T, Fujita M, Kato A, Narita Y, Nakasu Y. Clinical outcomes of brain metastases from hepatocellular carcinoma: a multicenter retrospective study and a literature review. Int J Clin Oncol. 2018;23:1095-1100. [PMID: 29968168 DOI: 10.1007/s10147-018-1312-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
53 Cai ZS, Chen MJ, Tang TY, Chang CW. Duodenum perforated after combination with sorafenib and radiotherapy for retroperitoneal lymph node metastasis of hepatocellular carcinoma. J Formos Med Assoc 2020;119:760-2. [PMID: 31677864 DOI: 10.1016/j.jfma.2019.10.009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Fukuda K, Okumura T, Abei M, Fukumitsu N, Ishige K, Mizumoto M, Hasegawa N, Numajiri H, Ohnishi K, Ishikawa H. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 2017;108:497-503. [PMID: 28012214 DOI: 10.1111/cas.13145] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
55 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
56 Sun JY, Yin T, Zhang XY, Lu XJ. Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol 2019;234:12116-21. [PMID: 30648254 DOI: 10.1002/jcp.28019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
57 Bai YH, Yun XJ, Xue Y, Zhou T, Sun X, Gao YJ. A novel oncolytic adenovirus inhibits hepatocellular carcinoma growth.J Zhejiang Univ Sci B. 2019;20:1003-1013. [PMID: 31749347 DOI: 10.1631/jzus.B1900089] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Berger NG, Tanious MN, Hammad AY, Miura JT, Mogal H, Clarke CN, Christians KK, Tsai S, Gamblin TC. External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database. J Surg Oncol 2017;116:307-12. [PMID: 28464313 DOI: 10.1002/jso.24661] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
59 Spallanzani A, Orsi G, Andrikou K, Gelsomino F, Rimini M, Riggi L, Cascinu S. Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Expert Rev Anticancer Ther. 2018;18:1069-1076. [PMID: 30220234 DOI: 10.1080/14737140.2018.1524297] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
60 Hu P, Fu Z, Liu G, Tan H, Xiao J, Shi H, Cheng D. Gadolinium-Based Nanoparticles for Theranostic MRI-Guided Radiosensitization in Hepatocellular Carcinoma. Front Bioeng Biotechnol 2019;7:368. [PMID: 31828068 DOI: 10.3389/fbioe.2019.00368] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
61 Luo J, Si Z, Li T, Li J, Zhang Z, Chen G, Qi H, Yao H. MicroRNA-146a-5p enhances radiosensitivity in hepatocellular carcinoma through replication protein A3-induced activation of the DNA repair pathway. American Journal of Physiology-Cell Physiology 2019;316:C299-311. [DOI: 10.1152/ajpcell.00189.2018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
62 Park HC, Yu JI, Cheng JC, Zeng ZC, Hong JH, Wang ML, Kim MS, Chi KH, Liang PC, Lee RC, Lau WY, Han KH, Chow PK, Seong J. Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer. 2016;5:162-174. [PMID: 27493892 DOI: 10.1159/000367766] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
63 Zhou Y, He P, Xie X, Sun C. Knockdown of SUMO1P3 represses tumor growth and invasion and enhances radiosensitivity in hepatocellular carcinoma. Mol Cell Biochem 2019;450:125-34. [PMID: 29905911 DOI: 10.1007/s11010-018-3379-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
64 Shen J, Hao J, Chen Y, Liu H, Wu J, Hu B, Wang Y, Zheng Y, Cai X. Neutrophil-mediated clinical nanodrug for treatment of residual tumor after focused ultrasound ablation. J Nanobiotechnology 2021;19:345. [PMID: 34715854 DOI: 10.1186/s12951-021-01087-w] [Reference Citation Analysis]
65 Bakshi N, Chand V, Sangal R, Duggal R. Radiation Induced Liver Injury: Collateral Damage Radiologically Simulating Interval Metastasis in Carcinoma Esophagus; a Diagnostic Dilemma Resolved Through Liver Biopsy. Int J Surg Pathol 2022;:10668969221095181. [PMID: 35470748 DOI: 10.1177/10668969221095181] [Reference Citation Analysis]
66 Lin Q, Huang X, Zhong C, Luo T, Zeng X, Chen S. Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database. Cancer Med 2019;8:515-26. [PMID: 30656831 DOI: 10.1002/cam4.1937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Yang X, Gao L, Guo Q, Li Y, Ma Y, Yang J, Gong C, Yi C. Nanomaterials for radiotherapeutics-based multimodal synergistic cancer therapy. Nano Res 2020;13:2579-94. [DOI: 10.1007/s12274-020-2722-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
68 Zhang H, Chang N, Han T, Ma S, Qu G, Liu H, Sun C, Cheng C, Zhou Q, Sun Y. Radiofrequency ablation versus stereotactic body radiotherapy for hepatocellular carcinoma: a meta-analysis. Future Oncol 2021. [PMID: 34278818 DOI: 10.2217/fon-2021-0263] [Reference Citation Analysis]
69 Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC, Hwang JJ. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model. Oncotarget 2016;7:85450-63. [PMID: 27863427 DOI: 10.18632/oncotarget.13398] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
70 Yoo GS, Yu JI, Cho S, Jung SH, Han Y, Park S, Oh Y, Lee B, Park HC, Lim DH, Choi MS, Won H. Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma. Radiother Oncol 2020;146:187-93. [PMID: 32179362 DOI: 10.1016/j.radonc.2020.02.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
71 Woodrell CD, Goldstein NE, Moreno JR, Schiano TD, Schwartz ME, Garrido MM. Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission. J Pain Symptom Manage 2021;61:940-947.e3. [PMID: 33035651 DOI: 10.1016/j.jpainsymman.2020.09.040] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Yoo GS, Yu JI, Park HC. Current role of proton beam therapy in patients with hepatocellular carcinoma. Int J Gastrointest Interv 2021;10:175-82. [DOI: 10.18528/ijgii210043] [Reference Citation Analysis]
73 Song JH, Jeong BK, Choi HS, Jeong H, Lee YH, Kim HJ, Kim TH, Jung WT, Lee OJ, Jang HS, Choi BO, Kang KM. Defining Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma Patients Treated with Stereotactic Body Radiotherapy. J Cancer 2017;8:4155-61. [PMID: 29187892 DOI: 10.7150/jca.21561] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
74 O'Leary C, Mahler M, Soulen MC. Curative-Intent Therapies in Localized Hepatocellular Carcinoma. Curr Treat Options Oncol 2020;21:31. [PMID: 32193784 DOI: 10.1007/s11864-020-0725-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
75 Toyama S, Shioyama Y, Suefuji H, Shinoto M, Matsumoto K, Terashima K, Hidaka M, Eguchi S, Abe K, Irie H, Eguchi Y. A case of the cirrhotic patient performed living donor liver transplantation after carbon-ion radiotherapy for hepatocellular carcinoma. Int Cancer Conf J 2018;7:65-70. [PMID: 31149517 DOI: 10.1007/s13691-018-0322-5] [Reference Citation Analysis]
76 Liu KY, Wang LT, Hsu SH, Wang SN. Homeobox Genes and Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E621. [PMID: 31058850 DOI: 10.3390/cancers11050621] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
77 Hu P, Cheng D, Huang T, Banizs AB, Xiao J, Liu G, Chen Q, Wang Y, He J, Shi H. Evaluation of Novel 64Cu-Labeled Theranostic Gadolinium-Based Nanoprobes in HepG2 Tumor-Bearing Nude Mice. Nanoscale Res Lett 2017;12:523. [PMID: 28875472 DOI: 10.1186/s11671-017-2292-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
78 Sayan M, Yegya-Raman N, Greco SH, Gui B, Zhang A, Chundury A, Grandhi MS, Hochster HS, Kennedy TJ, Langan RC, Malhotra U, Rustgi VK, Shah MM, Spencer KR, Carpizo DR, Nosher JL, Jabbour SK. Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Front Oncol 2019;9:345. [PMID: 31275846 DOI: 10.3389/fonc.2019.00345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
79 Nakano R, Ohira M, Kobayashi T, Ide K, Tahara H, Kuroda S, Shimizu S, Kimura T, Nagata Y, Aikata H, Chayama K, Ohdan H. Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: A propensity-matched analysis in a single institution. Surgery 2018;164:219-26. [PMID: 29801728 DOI: 10.1016/j.surg.2018.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
80 Guo Y, Chen J, Zhang Y, Guo Y, Jiang M, Dai Y, Yao X. Differentiating Cytokeratin 19 expression of hepatocellular carcinoma by using multi-b-value diffusion-weighted MR imaging with mono-exponential, stretched exponential, intravoxel incoherent motion, diffusion kurtosis imaging and fractional order calculus models. European Journal of Radiology 2022;150:110237. [DOI: 10.1016/j.ejrad.2022.110237] [Reference Citation Analysis]
81 Marsico M, Gabbani T, Lunardi S, Galli A, Biagini MR, Annese V. Percutaneous ultrasound-guided fiducial marker placement for liver cancer robotic stereotactic radio-surgery treatment: A comparative analysis of three types of markers and needles. Arab Journal of Gastroenterology 2017;18:83-6. [DOI: 10.1016/j.ajg.2017.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
82 Kim HG, Jang SS, Lee JS, Kim HS, Son CG. Panax ginseng Meyer prevents radiation-induced liver injury via modulation of oxidative stress and apoptosis. J Ginseng Res 2017;41:159-68. [PMID: 28413320 DOI: 10.1016/j.jgr.2016.02.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
83 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 1003] [Article Influence: 395.0] [Reference Citation Analysis]
84 Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol 2018; 24(28): 3090-3100 [PMID: 30065555 DOI: 10.3748/wjg.v24.i28.3090] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
85 Mastrocostas K, Jang HJ, Fischer S, Dawson LA, Munoz-Schuffenegger P, Sapisochin G, Kim TK. Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. Abdom Radiol (NY) 2019;44:1795-807. [PMID: 30710166 DOI: 10.1007/s00261-019-01901-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
86 R Ebrahim A, El-Mesery M, El-Karef A, Eissa LA. Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats. Can J Physiol Pharmacol 2018;96:1218-25. [PMID: 30205014 DOI: 10.1139/cjpp-2018-0445] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
87 Rabinel P, Dousse D, Muscari F, Suc B. Management of liver cancer. The Surgeon's point of view. Rep Pract Oncol Radiother 2017;22:176-80. [PMID: 28490990 DOI: 10.1016/j.rpor.2017.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
88 Wu JH, Guo JP, Shi J, Wang H, Li LL, Guo B, Liu DX, Cao Q, Yuan ZY. CMA down-regulates p53 expression through degradation of HMGB1 protein to inhibit irradiation-triggered apoptosis in hepatocellular carcinoma. World J Gastroenterol 2017; 23(13): 2308-2317 [PMID: 28428710 DOI: 10.3748/wjg.v23.i13.2308] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]